With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world.

The FTC suit targets the three biggest so-called pharmacy benefit managers, UnitedHealth Group's Optum Rx, CVS Health's ...

For too long, middlemen like pharmacy benefit managers have taken advantage of the complexity of the drug supply chain to ...

Eli Lilly’s stock has climbed almost 60% this year and trades for more than $900. The pharma giant also has seen soaring sales thanks to its dominance in the high-growth weight loss drug market.

The U.S. Food and Drug Administration has approved Indianapolis-based Eli Lilly's new treatment for moderate to severe eczema ...

How Eli Lilly’s Next 5 Years Could Play Out We expect Eli Lilly’s P/E ratio in 2025 to be 60 with an EPS of $19.11, resulting in a price target of $1140.00 This prediction is based on strong ...

Eli Lilly is investing $1.8 billion across two manufacturing sites in Ireland to boost production of its hugely popular obesity drug and a newly approved treatment for Alzheimer's, the drugmaker said ...

Eli Lilly & Co. is asking people who took copies of its blockbuster weight loss drug to give the company access to their medical records for safety reasons, a move that comes as it builds a case ...

Novo Nordisk and Eli Lilly are offering discounts to encourage more insurance coverage of the medicines, which carry price tags of over $1,000 a month. BMO Capital Markets managing director of ...

Pharmaceutical heavyweights like Bristol Myers Squibb, AstraZeneca, and Eli Lilly are betting big on radiopharmaceuticals, ...

The investments are part of Lilly's ongoing commitment to expand production for its top-selling diabetes and obesity drugs ...

Eli Lilly (NYSE: LLY) offers investors the same thing as many other big pharma companies: a certain level of security when it comes to revenue. Since people need their medicines regardless of the ...